The German Federal Ministry of Education and Research (BMBF) will be supplying the ZiSStrans research consortium with around four million euros over the next five years. The joint project, which is being coordinated at the Helmholtz Zentrum München, has the objective of investigating new possibilities to personalize radiotherapy of head and neck cancer.
The term ‘head-neck cancer’ is used to refer to various tumor types that occur in this part of the body, for example, cancer of the oral cavity or pharynx. Radiotherapy, either alone or combined with surgery and/or chemotherapy, is a central element in the complex treatment strategies.
Difficulties arise, however, if the tumors demonstrate so-called radiation resistance and do not respond to the treatment as desired, or if undesirable effects occur that make it necessary to stop the treatment.
“This is where the ZiSStrans project comes in,” explains coordinator Prof. Dr. Horst Zitzelsberger, head of the Radiation Cytogenetics Research Unit at the Helmholtz Zentrum München. “Our objective is to identify molecular signaling pathways and target structures for the radiation response and to examine them in patient studies.”
In this field, this step is called translation, which also explains the project's name. Because ZiSStrans is the translational follow-up project of “Targets and signaling pathways of radiation hypersensitivity and resistance” or ZiSS for short, which ran from 2012 to 2017.
The researchers particularly hope to gain new insights by comparing tumor and normal tissue. “The radiosensitivity of the surrounding healthy tissue limits the radiotherapy intensity which can be applied, because this is where undesirable effects can occur,” Zitzelsberger explains.
By understanding the signaling networks in the tumor and normal tissue, the researchers want to explore how the radiation response and resistance can be selectively influenced and how the treatment success can be improved by molecular substances.
A further focus of the research consortium is on personalized treatment. The use of new markers should make it possible to predict whether or not the particular patient will be able to profit from the planned action, even before the first radiation treatment. “In the future, we want to be able to say with great certainty that a particular patient is either a ‘responder’ or a ‘non-responder’, which means if the patient will respond to the treatment or if other options must be considered in advance,” says coordinator Zitzelsberger.
Of the total of four million euros that the BMBF will be providing to the project between 2017 and 2022, around 800,000 will be allocated to the Helmholtz Zentrum München. In addition to Research Unit Head Zitzelsberger, the groups of Dr. Julia Heß and Dr. Kristian Unger are also involved. Furthermore, the following partners are participating in the project:
• University Hospital of Munich (LMU, Department for Radiotherapy and Radiation Oncology, Prof. Lauber, Prof. Belka)
• Essen University Hospital (Institute of Cell Biology, Prof. Jendrossek, PD Dr. Klein)
• Medical Center – University of Freiburg (Center for Diagnostic and Therapeutic Radiology, Prof. Henke)
• Charité University Hospital Berlin (Institute of Pathology, Prof. Blüthgen)
• German Federal Office for Radiation Protection Neuherberg (Biological Radiation Effects, Dr. Hornhardt, Dr. Gomolka)
• Clinical cooperation group "Personalized radiotherapy of head-neck tumors" involving the Department for Radiotherapy and Radiation Oncology, University Hospital of Munich (LMU) and the Radiation Cytogenetics Research Unit, Helmholtz Zentrum München
Almost one year ago, researchers in the consortium had already developed a new method of predicting disease progression of certain brain tumors after standard treatment. In the journal ‘Oncotarget’, they were able to show that four miRNAs can provide the crucial indications. A direct application for a corresponding patent has already been made: https://www.helmholtz-muenchen.de/en/press-media/press-releases/all-press-releas...
In the thyroid gland, the researchers have also been able to identify markers for tumors induced by radiation: https://www.helmholtz-muenchen.de/en/press-media/press-releases/all-press-releas...
The Helmholtz Zentrum München, the German Research Center for Environmental Health, pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München is headquartered in Neuherberg in the north of Munich and has about 2,300 staff members. It is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members. http://www.helmholtz-muenchen.de/en
The Research Unit Radiation Cytogenetics (ZYTO) investigates radiation-induced chromosome and DNA damage in cell systems and human tumours. The focus is on clarifying the mechanisms associated with radiation-induced carcinogenesis and radiation sensitivity of tumour cells. The aim of this research is to find biomarkers associated with radiation-induced tumours in order to develop personalized radiation therapy for the stratification of patients. ZYTO is a part of the Department of Radiation Sciences (DRS). http://www.helmholtz-muenchen.de/zyto
Contact for the media:
Department of Communication, Helmholtz Zentrum München - German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg - Tel. +49 89 3187 2238 - E-mail: firstname.lastname@example.org
Scientific Contact at Helmholtz Zentrum München:
Prof. Dr. Horst Zitzelsberger, Helmholtz Zentrum München - German Research Center for Environmental Health, Research Unit Radiation Cytogenetics, Ingolstädter Landstr. 1, 85764 Neuherberg - Tel. +49 89 3187 3421, E-mail: Zitzelsberger@helmholtz-muenchen.de
Sonja Opitz | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
13.11.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau
Improving the understanding of death receptor functions in cells
07.11.2018 | Goethe-Universität Frankfurt am Main
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly
The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
15.11.2018 | Earth Sciences
15.11.2018 | Physics and Astronomy
15.11.2018 | Physics and Astronomy